Opendata, web and dolomites

DREAM SIGNED

Dux4-Regulated Expression and Activity by MATR3

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DREAM project word cloud

Explore the words cloud of the DREAM project. It provides you a very rough idea of what is the project "DREAM" about.

cells    despite    afflicts    activation    identification    sexes    stages    treatment    rational    indiscriminately    hypothesize    protects    children    laboratory    clarify    muscle    transcription    closer    molecular    aberrant    matr3    healthy    domain    toxic    strategy    myogenic    direct    genes    regulates    cytotoxic    dystrophy    loci    trials    expression    toxicity    regulator    examine    inhibiting    inhibitor    apoptotic    subjects    fshd    data    double    degeneration    dux4    treat    therapeutic    caused    continues    pro    wasting    cure    activates    peptidomimetic    interacting    restricted    tissues    molecule    mechanism    function    clinical    mis    muscular    transcriptional    action    homeobox    block    compelling    embryogenesis    characterizing    ages    first    blocking    option    disease    pathogenesis    elucidate    preliminary    innovation    facioscapulohumeral    stem    preventing    corollary    tools    models    prevent    body    representing    prevalent    patients    binding    adults    silenced   

Project "DREAM" data sheet

The following table provides information about the project.

Coordinator
OSPEDALE SAN RAFFAELE SRL 

Organization address
address: VIA OLGETTINA 60
city: MILANO
postcode: 20132
website: www.hsr.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 183˙473 €
 EC max contribution 183˙473 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2020
 Duration (year-month-day) from 2020-05-01   to  2022-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OSPEDALE SAN RAFFAELE SRL IT (MILANO) coordinator 183˙473.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Facioscapulohumeral muscular dystrophy (FSHD) is the most prevalent muscle disease that indiscriminately afflicts children and adults of all ages and both sexes. Despite several clinical trials, there continues to be no cure or therapeutic option available to FSHD patients. FSHD is caused by aberrant myogenic expression of the transcription factor double homeobox 4 (DUX4). In healthy subjects, DUX4 expression is restricted to stem cells and early stages of embryogenesis while being silenced in most tissues of the body. In FSHD, DUX4 mis-expression activates a pro-apoptotic transcriptional program leading to muscle wasting. Compelling data obtained in our laboratory identified MATR3 as the first direct DUX4 inhibitor and a therapeutic molecule. The identification of a novel regulator of DUX4 function now allows us to examine the potential of inhibiting the cytotoxic activity of DUX4 as a therapeutic strategy to treat FSHD, and represents the innovation of this proposal. The goal of the proposal is to fully elucidate the molecular mechanism through which MATR3 regulates DUX4 function in order to develop novel therapeutic approaches for blocking the aberrant activity of DUX4 in FSHD. Based on our preliminary data, I hypothesize that MATR3 protects from DUX4-induced toxicity by inhibiting DUX4 binding to target loci with the end result of preventing transcriptional activation of genes toxic to muscle cells. Characterizing MATR3 mechanism of action will provide possible therapeutic tools that we will evaluate in relevant models of FSHD. As a corollary, we propose that a peptidomimetic molecule representing the DUX4 interacting domain of MATR3 could be used to prevent the toxic effects of DUX4 expression in muscle cells from FSHD patients. This work is significant as it will clarify the molecular pathogenesis of the disease and bring us closer to a rational treatment to block muscle degeneration in FSHD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DREAM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DREAM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

ICL CHROM (2020)

DNA interstrand crosslink repair and chromatin remodelling

Read More  

TheaTheor (2018)

Theorizing the Production of 'Comedia Nueva': The Process of Play Configuration in Spanish Golden Age Theater

Read More  

GENI (2019)

Gender, emotions and national identities: a new perspective on the abortion debates in Italy (1971-1981).

Read More